Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal
Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeuti...
Gespeichert in:
| Veröffentlicht in: | Journal of B.U. ON. 2018-12, Vol.23 (7), p.19-23 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 23 |
|---|---|
| container_issue | 7 |
| container_start_page | 19 |
| container_title | Journal of B.U. ON. |
| container_volume | 23 |
| creator | Samartzis, Konstantinos Thomakos, Nikolaos Liontos, Michael Kollia, Dimitra Malakasis, Anastasios Haidopoulos, Dimitrios Bamias, Aristotelis Rodolakis, Alexandros Loutradis, Dimitrios |
| description | Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2211953349</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2211953349</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-56b92c23666a1f9256a0b639d4f607e94f83554554fc788fba3fd770671c39343</originalsourceid><addsrcrecordid>eNo1kEtrwzAQhH1oaUKav1B07MWghy1bpxJCH4FCL-3ZrOV1rGLJriQXcu4fr0LTZWHZmY85zFW2ZoxWOZW8XGXbED5pGkmZVPVNthK04jz56-znEIiJJA5IvDkOkdjJokvCRIzT49IhGU4z-gR4a3QSo4f0mzg5hJHoAe10NmE-EQgkRHAd-C6BZPoGb8ARDU6jJxYcHPGc_kB2xCPMswcTYLzNrnsYA24vd5N9PD2-71_y17fnw373ms-csZiXslVccyGlBNYrXkqgrRSqK3pJK1RFX4uyLNL2uqrrvgXRd1VFZcW0UKIQm-z-L3f209eCITbWBI3jCA6nJTSpEqZKIQqV0LsLurQWu2b2xoI_Nf_FiV8DwGsD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2211953349</pqid></control><display><type>article</type><title>Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Samartzis, Konstantinos ; Thomakos, Nikolaos ; Liontos, Michael ; Kollia, Dimitra ; Malakasis, Anastasios ; Haidopoulos, Dimitrios ; Bamias, Aristotelis ; Rodolakis, Alexandros ; Loutradis, Dimitrios</creator><creatorcontrib>Samartzis, Konstantinos ; Thomakos, Nikolaos ; Liontos, Michael ; Kollia, Dimitra ; Malakasis, Anastasios ; Haidopoulos, Dimitrios ; Bamias, Aristotelis ; Rodolakis, Alexandros ; Loutradis, Dimitrios</creatorcontrib><description>Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease.</description><identifier>ISSN: 1107-0625</identifier><identifier>PMID: 30722107</identifier><language>eng</language><publisher>Greece</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy, Cancer, Regional Perfusion - mortality ; Combined Modality Therapy ; Cytoreduction Surgical Procedures - mortality ; Disease Management ; Disease-Free Survival ; Female ; Humans ; Hyperthermia, Induced - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Survival Rate</subject><ispartof>Journal of B.U. ON., 2018-12, Vol.23 (7), p.19-23</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30722107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samartzis, Konstantinos</creatorcontrib><creatorcontrib>Thomakos, Nikolaos</creatorcontrib><creatorcontrib>Liontos, Michael</creatorcontrib><creatorcontrib>Kollia, Dimitra</creatorcontrib><creatorcontrib>Malakasis, Anastasios</creatorcontrib><creatorcontrib>Haidopoulos, Dimitrios</creatorcontrib><creatorcontrib>Bamias, Aristotelis</creatorcontrib><creatorcontrib>Rodolakis, Alexandros</creatorcontrib><creatorcontrib>Loutradis, Dimitrios</creatorcontrib><title>Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal</title><title>Journal of B.U. ON.</title><addtitle>J BUON</addtitle><description>Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy, Cancer, Regional Perfusion - mortality</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures - mortality</subject><subject>Disease Management</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Hyperthermia, Induced - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Survival Rate</subject><issn>1107-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtrwzAQhH1oaUKav1B07MWghy1bpxJCH4FCL-3ZrOV1rGLJriQXcu4fr0LTZWHZmY85zFW2ZoxWOZW8XGXbED5pGkmZVPVNthK04jz56-znEIiJJA5IvDkOkdjJokvCRIzT49IhGU4z-gR4a3QSo4f0mzg5hJHoAe10NmE-EQgkRHAd-C6BZPoGb8ARDU6jJxYcHPGc_kB2xCPMswcTYLzNrnsYA24vd5N9PD2-71_y17fnw373ms-csZiXslVccyGlBNYrXkqgrRSqK3pJK1RFX4uyLNL2uqrrvgXRd1VFZcW0UKIQm-z-L3f209eCITbWBI3jCA6nJTSpEqZKIQqV0LsLurQWu2b2xoI_Nf_FiV8DwGsD</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Samartzis, Konstantinos</creator><creator>Thomakos, Nikolaos</creator><creator>Liontos, Michael</creator><creator>Kollia, Dimitra</creator><creator>Malakasis, Anastasios</creator><creator>Haidopoulos, Dimitrios</creator><creator>Bamias, Aristotelis</creator><creator>Rodolakis, Alexandros</creator><creator>Loutradis, Dimitrios</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201812</creationdate><title>Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal</title><author>Samartzis, Konstantinos ; Thomakos, Nikolaos ; Liontos, Michael ; Kollia, Dimitra ; Malakasis, Anastasios ; Haidopoulos, Dimitrios ; Bamias, Aristotelis ; Rodolakis, Alexandros ; Loutradis, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-56b92c23666a1f9256a0b639d4f607e94f83554554fc788fba3fd770671c39343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy, Cancer, Regional Perfusion - mortality</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures - mortality</topic><topic>Disease Management</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Hyperthermia, Induced - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Survival Rate</topic><toplevel>online_resources</toplevel><creatorcontrib>Samartzis, Konstantinos</creatorcontrib><creatorcontrib>Thomakos, Nikolaos</creatorcontrib><creatorcontrib>Liontos, Michael</creatorcontrib><creatorcontrib>Kollia, Dimitra</creatorcontrib><creatorcontrib>Malakasis, Anastasios</creatorcontrib><creatorcontrib>Haidopoulos, Dimitrios</creatorcontrib><creatorcontrib>Bamias, Aristotelis</creatorcontrib><creatorcontrib>Rodolakis, Alexandros</creatorcontrib><creatorcontrib>Loutradis, Dimitrios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of B.U. ON.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samartzis, Konstantinos</au><au>Thomakos, Nikolaos</au><au>Liontos, Michael</au><au>Kollia, Dimitra</au><au>Malakasis, Anastasios</au><au>Haidopoulos, Dimitrios</au><au>Bamias, Aristotelis</au><au>Rodolakis, Alexandros</au><au>Loutradis, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal</atitle><jtitle>Journal of B.U. ON.</jtitle><addtitle>J BUON</addtitle><date>2018-12</date><risdate>2018</risdate><volume>23</volume><issue>7</issue><spage>19</spage><epage>23</epage><pages>19-23</pages><issn>1107-0625</issn><abstract>Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease.</abstract><cop>Greece</cop><pmid>30722107</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1107-0625 |
| ispartof | Journal of B.U. ON., 2018-12, Vol.23 (7), p.19-23 |
| issn | 1107-0625 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2211953349 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy, Cancer, Regional Perfusion - mortality Combined Modality Therapy Cytoreduction Surgical Procedures - mortality Disease Management Disease-Free Survival Female Humans Hyperthermia, Induced - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Survival Rate |
| title | Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A31%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20it%20the%20right%20moment%20to%20include%20hyperthermic%20intraperitoneal%20chemotherapy%20as%20standard%20in%20ovarian%20cancer%20management?%20A%20reappraisal&rft.jtitle=Journal%20of%20B.U.%20ON.&rft.au=Samartzis,%20Konstantinos&rft.date=2018-12&rft.volume=23&rft.issue=7&rft.spage=19&rft.epage=23&rft.pages=19-23&rft.issn=1107-0625&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2211953349%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2211953349&rft_id=info:pmid/30722107&rfr_iscdi=true |